drugset / Trial / NCT00408603
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
Timeline
- Start
- 2006-12-20
- Primary completion
- 2010-06-09
- Completion
- 2010-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vosaroxin | Small molecule | 48 mg/m2 | — |
| Subject | Vosaroxin | Small molecule | 60 mg/m2 | — |
| Subject | Vosaroxin | Small molecule | 75 mg/m2 | — |